Published in final edited form as:

Trends Biochem Sci. 2013 August ; 38(8): 394–402. doi:10.1016/j.tibs.2013.05.005.

Menin: a scaffold protein that controls gene expression and cell signaling

Smita Matkar^{*}, Austin Thiel^{*}, and Xianxin Hua[§]

Department of Cancer Biology, Abramson Family Cancer Research Institute, Abramson Cancer Center, the University of Pennsylvania Perelman School of Medicine, 421 Curie Blvd., Philadelphia, PA 19104, USA

Abstract

The protein menin is encoded by the *MEN1* gene, which is mutated in patients with multiple endocrine neoplasia type 1 (MEN1) syndrome. Although menin acts as a tumor suppressor in endocrine organs, it is required for leukemic transformation in mouse models. Menin possesses these dichotomous functions likely because it can both positively and negatively regulate gene expression as well as interact with a multitude of proteins with diverse functions. Here we review the recent progress in understanding the molecular mechanisms by which menin functions. The crystal structures of menin with different binding partners reveal that menin is a key scaffold protein that functionally crosstalks with various partners to regulate gene transcription and interplay with multiple signaling pathways.

Keywords

menin; scaffold protein; gene transcription; cell signaling

Menin : an orphan protein mutated in an inherited tumor syndrome

The menin protein is encoded by the *MEN1* gene, which is mutated in patients with multiple endocrine neoplasia type 1 (MEN1) syndrome^{1, 2}. MEN1 syndrome is a dominantly inherited disease that is characterized by tumor formation in endocrine organs including the pituitary gland, the parathyroid gland and pancreatic islets^{3–7}. The majority of patients with the inherited form of this disease have one germline mutation in the *MEN1* gene, with loss of heterozygosity (LOH) at the *MEN1* alleles in the endocrine tumor, highlighting menin as a bona fide tumor suppressor in endocrine organs. These mutations spread throughout the coding region of the gene, with no obvious mutation hotspots^{5, 8}. *MEN1* is also frequently mutated in patients with sporadic parathyroid⁹ and pancreatic endocrine tumors^{8, 10}. Consistently, mice with heterozygous *Men1* mutation phenocopy the human MEN1 syndrome^{11–13}. Complete *Men1* ablation in the mouse is embryonic lethal at E11.5–13.5, with deficiencies in multiple organs¹¹.

© 2013 Elsevier Ltd. All rights reserved

[§]Corresponding author: Xianxin Hua, Tel. 215-746-5567, Fax 215-746-5525, huax@mail.med.upenn.edu.

^{*}Equal contribution to the work

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest No conflicts of interests are declared by any of the authors.

Menin consists of 610 residues and is conserved from *Drosophila* to humans¹⁴, but is not found in yeast or *Caenorhabditis elegans*, indicating that it is evolutionarily a relatively new gene. While menin is ubiquitously expressed in various organs during mouse embryonic development^{15, 16}, its function is tissue-specific, sometimes displaying opposing roles between different organs. For instance, it suppresses tumorigenesis in endocrine organs, yet is essential for leukemogenesis^{17, 18}.

It has also been reported that menin plays a role in suppressing hyperplasia or tumors in several other organs, such as the lung^{19, 20}, prostate²¹, and breast²², and it exacerbates diabetes in mouse models^{23–25}. Menin also influences the function of other organs such as bone^{26–31} and liver^{32, 33}. Detailed mechanisms for how menin impacts these organs are less clear, but it likely functions via regulating various distinct signaling pathways. Menin itself is also regulated by multiple signaling proteins such prolactin²³ and transforming growth factor beta (TGF- β), and by posttranslational modifications such as phosphorylation and SUMOylation. Additionally, MEN1 disease-associated single amino acid substitutions can lead to enhanced polyubiquitylation and degradation via proteasomal pathway.^{34–37}

Because menin lacks domains that are homologous to other proteins, it is challenging to elucidate its biochemical function. As such, intensive efforts have been made by many groups to identify menin-interacting proteins, in the hopes of finding clues about how menin biochemically suppresses tumorigenesis, as previously reviewed^{38, 39}. These menin partners provide valuable information regarding the biochemical function of menin. However, the detailed underlying structural mechanism has been elusive. Recent progress in elucidating the crystal structure of menin, coupled with the revelation that menin crosstalks with various signaling pathways, provide new insights into how menin controls gene expression and cell signaling^{40, 41}. This review focuses on the latest progress in understanding how menin, as a scaffold protein, controls gene expression and interplays with multiple signaling pathways to control cell behavior. As certain studies were performed in one cell line or one model system and in some situations only a limited number of studies were performed, caution is to be exercised regarding generalizing the role of menin and underlying mechanisms in these situations.

Menin interacts with proteins involved in regulating gene transcription and cell signaling

Although menin is ubiquitously expressed, its expression levels vary from tissue to tissue^{15, 23, 42}. Menin is primarily a nuclear protein, but lesser amounts are also detectable in the cytoplasm and even the cell membrane. Its nuclear localization sequences (NLSs), located in its C-terminal region, can directly interact with DNA in a sequence-independent manner^{43, 44}. Menin-interacting proteins can be classified into four main categories based on their cellular role in context to their association with menin: transcription activators, transcription repressors, and cell signaling proteins, and the other remaining interacting partners, which have diverse functions ranging from regulation of DNA repair to the structural integrity of the cell (Figure 1A). Menin-interacting transcriptional activators include transcription factors c-Myb, Protein-energy malnutrition (Pem) and runt-related transcription factor 2 (Runx2)^{45, 46, 29, 47}, and histone modifiers such as MLL1–2 (mixed lineage leukemia proteins) and histone H3 lysine 4 (H3K4) methyltransferases^{48, 49}. The transcriptional repressors that directly or indirectly interact with menin include JunD, NF κ B, homeobox HB9 Hlx^{50, 51, 52}, histone deacetylases 1/2 (HDAC1/2), the histone deacetylase Sirt1, the histone H3 lysine 27 methyltransferase EZH2, and protein arginine methyltransferase 5 (PRMT5)^{20, 53–55}. Notably, menin also interacts with multiple proteins that mediate several signaling pathways, such as the SMAD proteins, which transduce TGF β signaling^{29, 56}; β -catenin, a member of the Wnt signaling pathway^{57–60}; nuclear receptors

such as estrogen receptor and PPAR γ ; and Ras-activating protein SOS1^{19, 61, 62}. The physiological and genetic impact of the interaction between menin and many of its interacting proteins in model organisms remains to be explored. It is noteworthy that these signaling proteins often can also act as either transcription activators or repressors, however for the purposes of this discussion we classify them based on their activity in the context of their interaction with menin.

Our group and others have proposed that menin might act as a scaffold or adaptor protein to interact with other proteins in controlling gene transcription, based on cellular and biochemical studies^{44, 63}. This concept is consistent with the observation that menin distributes in a broad spectrum in gel filtration chromatography⁵⁴, and that menin binds to thousands of gene loci in various cell lines^{64, 65}. However, until recently the crystal structure of menin was not known, hindering the understanding of how menin interacts with its partners to exert its functions.

Crystal structure of menin and its interacting partners

Great efforts by many groups have been made to solve the crystal structure of menin. It has been challenging to obtain high quality menin protein crystals to decipher its structure. However, Huang et al. and Murai et al. have recently succeeded in solving the structure of menin alone^{40, 41}, in complex with an MLL1 peptide (Fig. 1B), in a ternary complex with MLL1 and LEDGF (Lens Epithelium-Derived Growth Factor) (Fig. 1C), or in complex with a peptide from JunD (Fig. 1D)⁴⁰.

The crystal structure of menin looks like a curved left hand, in which the N-terminal domain is represented by long β -hairpin, transglutaminase-like domain that resembles a thumb, the middle region adopts the shape of the palm, and the C-terminus resembles curved fingers (Fig. 1B). Notably, the 'palm' forms a deep pocket that is occupied by the conserved MLL1 peptide (Fig. 1B). Mutagenesis studies show that the residues in either MLL1 or the menin pocket that mediate the menin--MLL1 interaction are crucial for binding each other as well as for the menin-mediated upregulation of Hox genes⁴⁰.

Biochemical studies show that menin not only interacts with MLL1, but also interacts simultaneously with LEDGF, a protein important for MLL-AF9 induced leukemia⁶³. The crystal structure of menin-MLL1-LEDGF clearly shows that the N-terminal region of MLL1 (yellow, Fig. 1C) binds the deep central pocket of menin, and the further downstream sequence of MLL1 loops around the N-terminal part of menin, forming an alpha helix that directly contacts the menin N terminus. On the top of the "V" shape structure that is co-formed by the alpha helix of MLL1 and the surface of the N-terminal part of menin, LEDGF (red, Fig. 1C) directly interacts with both MLL1 and menin. This is strong evidence demonstrating that menin acts as a scaffold protein to interact with multiple proteins. Consistent with this notion, a mutation in menin at the LEDGF-interaction site diminishes the ability of menin to promote expression of Hoxc8. Further work is needed to determine how menin structurally interacts with other partners.

Similar to its interaction with MLL1, Menin also binds JunD via its central pocket. The region of JunD that binds menin spans residues 27–47, and is known as the menin-binding motif (JunD_{MBM}) (Fig. 1D)⁴⁰. Comparison of the JunD_{MBM} with the MLL1 peptide that binds menin (MLL1_{MBM}) reveals a conserved sequence (FPXXP). Indeed, the co-crystal of menin and the JunD peptide shows that JunD_{MBM} and MLL1_{MBM} bind the menin pocket with the same orientation (Fig. 1B and D). MLL1_{MBM} effectively competes out JunD binding to menin⁴⁰, demonstrating that menin can use the same pocket to bind either MLL1 or JunD. MLL2 also binds to menin via a similar conserved sequence. It remains to be determined whether menin can also interact with other proteins containing similar

sequences. Binding of menin to MLL1 serves to recruit these proteins to promoters of the genes, leading to an increase in gene transcription⁴⁰.

Menin activates gene transcription

Menin upregulates the expression of cyclin-dependent kinase (CDK) inhibitors (CDKIs) p18 and p27^{42, 66, 67}, thereby reducing beta cell proliferation. It activates transcription of the CDKIs at least partly via MLL1, which adds tri-methylation to histone H3 at lysine 4 (H3K4me3), a chromatin modification associated with transcriptional activation^{48, 66, 67} (Fig. 2A). Consistent with these findings, genetic ablation of RBP2, a histone H3 lysine 4 demethylase, reduced the development of insulinoma in a beta cell-specific *Men1* knockout mouse model⁶⁸. Whether a DNA sequence-specific factor recruits menin-MLL1 to the loci, and which factor that might be, remains unclear.

The *MLL1* gene can undergo chromosomal translocations with one of various partner genes, resulting in the expression of MLL1 fusion proteins (MLL-FPs) that can induce leukemia. In these circumstances leukemogenesis is driven by c-Myb, a transcription factor that directly binds menin and likely recruits MLL1-FP, wild-type (WT) MLL1, and LEDGF to Hoxa9 and Meis1 gene loci to promote their expression (Fig. 2B)^{40, 45, 63, 69}. Deletion of menin in these leukemia cells abolishes recruitment of WT MLL1 and MLL1-FPs and decreases H3K4me3 at these gene loci, demonstrating that menin is an essential cofactor for MLL1 function (Fig. 2B)⁷⁰. Consistent with their role in promoting Hoxa9 and Meis1 expression, MLL1 fusion proteins are found in complexes associated with enhancing transcriptional activation, including the Dot1L complex, which methylates H3K79, and the pTEFb complex, which mediates transcriptional elongation^{71, 72}.

As menin plays an important role in regulating gene expression through interaction with various partners such as MLL1 and MLL1 fusion protein, small molecule inhibitors that block menin-MLL1 interaction were developed. These inhibitors were shown to suppress menin--MLL1-dependent expression of Hox genes and inhibit proliferation of MLL1 fusion-transformed leukemia cells⁷³. These findings support a new therapeutic strategy for aggressive leukemias with MLL1 rearrangements. Further optimization of these menin inhibitors yielded another compound (MI-2-2) that binds to menin with low nanomolar affinity ($K(d) = 22\text{nM}$) and very effectively disrupts the interaction between menin and MLL1⁷⁴. Moreover, co-crystallization of the human menin protein with MI-2-2 gave a high resolution (1.6Å) structure that displayed a close interaction between menin and MI-2-2. MI-2-2 has increased efficacy in blocking the menin--MLL1 interaction and expression of Hox genes compared to the earlier compounds⁷⁴. These findings provide a structural basis to design better inhibitors to effectively inhibit the menin-MLL1 interaction.

Consistent with these findings, recently reported structure-based design of cyclic peptidomimetics, based on the co-crystal structure of menin--MLL1 peptide⁷⁵, also generated a potent macrocyclic peptidomimetic compound that binds to menin with a K_i value of 4.7 nM, more than 600 times more potent than the corresponding acyclic MLL1 peptide⁷⁵. Collectively, this fast progress in designing small molecule compounds to inhibit menin--MLL1 interaction, and expression of menin--MLL1 targets such as the Hox genes in leukemia, pave the way to develop better compounds with ideal pharmacokinetics, and might eventually lead to effective drugs to treat aggressive AML.

Menin suppresses gene transcription

Menin has also been shown to repress gene transcription directly or indirectly. Recent studies have identified more factors that repress gene transcription through association with menin, such as various chromatin-modifying enzymes. Menin also regulates the expression

of miRNAs and indirectly controls post-transcriptional expression. Moreover, menin directly interacts with JunD (as discussed previously), and represses JunD-induced transcription through its interaction with the co-repressor mSin3A and its associated HDAC (Fig. 3A)^{50, 55}. It also represses the G2-M phase transition by repressing cyclin B2 expression, partly via recruiting HDAC3 to its promoter⁷⁶.

Menin inhibits JunD-mediated gene transcription through an additional mechanism involving competition for a binding partner⁴⁰. c-Jun N-terminal kinase (JNK) normally phosphorylates JunD, activating JunD-induced gene expression. The consensus JNK-docking domain (D-domain) in JunD contains a cluster of basic amino acids preceding two leucine residues. The JunD_{MBM} sequence partially overlaps with a putative D-domain of JunD (JunDD) (Fig. 3B)⁷⁷. Both the basic residues and the leucine residues in JunDD are essential for JNK to dock on (or bind to) JunD and phosphorylate it, as well as for binding by menin (Fig. 3B). As such, menin binding to JunD blocks JNK-mediated phosphorylation and activation of JunD. Menin and JunD both bind to the promoter of the endogenous *Gastrin* gene and suppress its expression⁴⁰. These findings unravel a new means for menin-mediated suppression of JunD activity and provide a structural basis for the mechanism of suppression (Fig. 3B). These findings also help explain why JunD activates proliferation of mouse embryonic fibroblasts (MEFs) in the absence of menin but suppresses proliferation in its presence; presumably, JunD binds promoters of pro-proliferative genes, and the presence or absence of menin controls whether JunD inhibits or activates expression of these genes, respectively⁷⁸.

Menin also directly interacts with the p65 subunit of NF- κ B and represses NF- κ B-dependent transcription, as shown by luciferase reporter assays in cultured cells⁵¹. It has recently been reported that menin inhibits NF- κ B-mediated transactivation via recruiting Sirt1, a histone deacetylase, to deacetylate lysine 310 (K310) of p65 in hepatocellular carcinoma cells (Fig. 4)⁵³. It remains unclear whether menin-induced and Sirt1-mediated deacetylation of p65 represses expression of the endogenous targets of NF- κ B.

Menin is also reported to repress expression of the *PTN* gene, which encodes a pro-proliferative receptor, pleiotrophin, in lung cancer cells²⁰. Both menin and a polycomb repressive complex 2 (PRC2) bind to the PTN gene promoter and increase the repressive chromatin mark H3K27me3 at the locus (Fig. 3C). A direct interaction between menin and EZH2, the PRC2 enzyme that catalyzes H3K27 trimethylation, has not been demonstrated.

Menin also directly interacts with protein arginine methyltransferase 5 (PRMT5), a negative regulator of gene transcription⁵⁴, and recruits it to the promoter of the *Gas1* gene, a crucial factor for binding of Sonic hedgehog (Shh) ligand to its receptor⁷⁹. Thus, menin antagonizes Shh signaling, partly via increasing PRMT5-mediated repressive histone arginine dimethylation (H4R3me2) at the *Gas1* promoter (Fig. 3D).

Menin was reported to repress gene expression posttranscriptionally via upregulation of microRNA expression, which can reduce protein translation or the stability of the target mRNA. Specifically, menin induces expression of microRNA-26a (miR-26a) by binding to the promoter of the miR-26a gene⁸⁰. miR-26a targets and reduces the protein expression of the bone morphogenetic protein (BMP) signaling effector SMAD1, antagonizing the osteoblastic differentiation of human adipose tissue-derived stem cells by BMP. Interestingly, menin also promotes BMP signaling by binding SMADs at target loci and promoting expression of SMAD-target genes. Thus, induction of miR-26a by menin is likely a dampening or desensitizing mechanism for menin-mediated BMP signaling (Fig. 4). It remains unclear whether or how these various modes operate in different types of cells or for different target genes.

Menin regulates multiple signaling pathways

TGF β signaling pathway

Menin directly interacts with the TGF β downstream signaling molecule SMAD3 in COS cells⁵⁶. Menin knockdown (KD) reduces SMAD3 binding to DNA in GH4C1 cells, a pituitary endocrine tumor cell line, suggesting a role for menin in recruiting SMAD3 to target genes to regulate their expression. Consistently, menin KD reduces the effect of TGF β -induced inhibition of proliferation⁵⁶.

BMP signaling

Menin also regulates BMP signaling, which is critical for bone development²⁹. Consistent with this role, *Men1*-null embryos display defects in cranial and facial development²⁹. Menin is required for BMP-dependent multipotent mesenchymal stem cell commitment to the osteoblast lineage, and it facilitates this commitment through its interaction with the BMP effectors SMAD1/5 and their binding partner Runx2³¹. At later stages of differentiation menin inhibits differentiation, likely through inhibiting JunD function³⁰. These results indicate that menin-mediated regulation of various signaling pathways may be not only tissue-specific, but also specific to a certain stage of differentiation.

Wnt Signaling

Wnt signaling stimulates pancreatic islet β cell proliferation, possibly by increasing expression of paired-like homeodomain 2 (Pitx2)⁸¹. At least part of the effects of Wnt on β cells is mediated by the canonical Wnt effector and transcription factor β -catenin. Overexpression of menin reduces nuclear accumulation of β -catenin and therefore its transcriptional activity in MEFs, in part by directly interacting with β -catenin and excluding it from the nucleus (Fig. 4)⁵⁸. By contrast, menin was shown to be crucial for canonical Wnt/ β -catenin signaling in cultured rodent islet tumor cells via interaction with β -catenin⁵⁹. It is possible that menin may promote Wnt signaling in certain stages of islet tumor development or inhibit Wnt signaling to prevent β cells from tumorigenesis (Fig. 4). Further detailed biochemical and genetic mechanisms remain to be explored.

Nuclear receptor signaling

Menin interacts with several nuclear receptor transcription factors including estrogen receptor (ER α) and PPAR γ ^{61, 62}. Menin directly interacts with ER α in a hormone-dependent manner and is recruited to the ER α target gene, trefoil factor 1 (TFF1). There, it increases the active histone mark H3K4me3, likely via recruitment of MLL, and activates target gene expression (Fig. 4). Menin also binds to ER α to enhance its activity in MCF7 breast cancer cells⁸², and menin expression correlates with a poorer prognosis in ER-positive breast cancer patients treated with tamoxifen. It is not yet clear whether menin can regulate endogenous ER targets to promote proliferation or survival of normal or transformed breast epithelial cells.

Ras signaling

Consistent with a role for menin in suppressing proliferation, menin overexpression slows the proliferation of Ras-transformed NIH-3T3 cells⁸³. Menin inhibits ERK-dependent phosphorylation, a downstream target in Ras pathway, and activation of JunD⁸⁴. Consistently, menin also inhibits ERK activation and lung cancer cell migration⁸⁵. Upstream of extracellular signal-regulated kinase (ERK), menin antagonizes Ras/ERK signaling by reducing the level of active Ras-GTP. This is achieved at least partly by preventing the Ras guanine nucleotide exchange factor Son of Sevenless (SOS1), and its adaptor, growth factor receptor-bound protein 2 (GRB2), from binding to Ras in lung cancer cells (Fig. 4)¹⁹. It

remains to be determined how menin blocks SOS1 from binding to Ras and precisely how menin inhibits ERKs.

Akt and FOXO signaling

Menin has been reported to interact with the protein kinase Akt1 in cultured cells and mouse pancreata and reduce the level of active Akt1, at least in part by reducing its kinase activity⁸⁶. Menin suppresses both Akt1-dependent proliferation and anti-apoptotic activity in nonendocrine and endocrine cells, partly by reducing the translocation of Akt1 from the cytoplasm to the plasma membrane (Fig. 4). It is unclear how menin prevents translocation of Akt1 to the cell membrane. Further work will be needed to determine the role of Akt1 in menin-mediated suppression of endocrine tumors, which can be done using tissue-specific double knockout of Men1 and Akt1. Menin is also reported to interact with transcription factor FOXO1 in the cytoplasm of hepatocytes⁸⁷, but it is unclear whether menin directly or indirectly interacts with FOXO1 and what the biological consequence of this interaction is. As the Akt/mTOR pathway is upregulated in pancreatic neuroendocrine tumors, it would be important to investigate precisely how menin suppresses this pathway.

Hedgehog signaling

Menin directly interacts with PRMT5, a negative regulator of gene transcription⁵⁴, and recruits PRMT5 to the promoter of the *Gas1* gene, a crucial factor for binding of Sonic hedgehog (Shh) ligand, to activate the Hh signaling, a pro-proliferative pathway (Fig. 3D).

Overall, it has been proposed that menin plays an important and tissue specific role in various signaling pathways, ranging from Ras to Akt to Hedgehog signaling. However, more experimental evidence is needed to completely understand the function of menin with reference to these signaling pathways.

Regulation of menin by various proteins and signaling pathways

Prolactin pathway

It has been reported that menin influences islet growth in pregnant mice²³. Prolactin, a hormonal regulator of pregnancy, represses islet menin expression via the Stat5/Bcl6 axis, leading to enhanced β cell proliferation during mouse pregnancy. Consistent with these findings, another recent report also shows that prolactin signaling and menin regulate pregnancy-induced β cell proliferation⁸⁸.

TGF β pathway

TGF β stimulation leads to the upregulation of menin expression in rat GH4C1 cells, suggesting crosstalk between menin and TGF β signaling²⁹. Consistently, menin expression is also upregulated by TGF β in MLL-AF9-transformed leukemia cells and mouse hepatocytes⁸⁹. As menin also interacts with SMAD3, a TGF β signal transducer, to increase gene expression (Fig. 4), these studies suggest a potential positive feedback loop. It is unclear how TGF β upregulates menin expression and whether the crosstalk between menin and TGF β signaling operates in animal models.

Somatostatin pathway

Gastrin is a peptide hormone that stimulates gastric acid secretion from parietal cells of the stomach, while Somatostatin is a peptide hormone and inhibitor of gastrin secretion as well as expression. It has been proposed that menin inhibits the expression of gastrin. Menin protein expression was reduced in the gastrointestinal system of somatostatin-null mice⁹⁰. Mice treated with the somatostatin analog octreotide show an increased number of menin-

expressing cells, menin mRNA, and menin protein expression predominantly in the duodenum. Menin induction appears to depend on suppression of protein kinase A (PKA). Whether and how the somastatin pathway regulates PKA to induce the expression of menin remains to be elucidated.

Glucose and the PI3K/Akt pathway

Menin acts as a negative regulator of β -cell proliferation, especially during pregnancy²³. Also, acute ablation of menin prevents the development of streptozotocin-induced diabetes and reverses pre-existing diabetes in several mouse diabetes models^{24, 25}. Short term glucose stimulation reduced menin levels and increased proliferation in INS1 insulinoma cells and primary rat islets in a PI3K/Akt signaling-dependent manner⁹¹. It has been reported that PI3K/Akt reduces expression of menin by phosphorylating and inhibiting the transcription factor FOXO1, which binds the promoter and stimulates transcription of the *Men1* gene⁹¹. It remains to be explored whether this mechanism operates in primary islets and mouse diabetes models.

Silencing of the MEN1 expression by K-Ras-induced DNA methylation or microRNA

K-Ras-activation inhibits menin expression via DNMT1-dependent DNA de-methylation of the promoter of the *MEN1* gene in human lung cancer cells¹⁹. Moreover, Luzi et al. discovered that miR-24-1 binds to the 3'UTR of *MEN1* mRNA, and reduces *MEN1* expression posttranscriptionally, unraveling another means of suppression of the *MEN1* gene⁹².

Post-translational modifications of menin

Menin is post-translationally modified by SUMOylation, phosphorylation and ubiquitylation. Menin is SUMOylated by SUMO1 at Lysine 591³⁵. Point mutations associated with the MEN1 disease lead to rapid degradation of menin by the ubiquitin-proteasome pathway in 293T cells³⁴. Menin is specifically phosphorylated at Serine 394 on treatment with γ IR and UV. Menin is also phosphorylated at Ser487 dynamically and at Ser543 constitutively, but the impact of phosphorylation on menin function remains unclear⁹³.

Menin-mediated regulation of integrity of genome

Menin interacts with various proteins involving DNA replication and repair, such as checkpoint suppressor 1 (CHES1)⁹⁴, and menin is localized to telomeres during meiosis⁹⁵, suggesting a role for menin in telomere maintenance. Recently, mutations in chromatin modifier Daxx/ATRAX genes as well as the *MEN1* gene were identified in pancreatic neuroendocrine tumors (PNETs)¹⁰. Daxx is localized at the telomere in PNETs, and it is not yet clear whether there is any functional crosstalk between menin and Daxx/ATRAX in regulating the telomere. Whether and how these interactions of menin with DNA modifiers influence the biochemical function of menin in normal cells or disease states is not yet clear.

Concluding remarks

Recently rapid progress has been made in understanding the molecular and biochemical functions of menin. In particular, as the crystal structures of menin with several of its binding partners have been solved, and these new findings have established menin as a key scaffold protein that can functionally crosstalk with various partners in controlling a diverse range of biological functions. Menin positively or negatively controls gene transcription by interacting with distinct proteins. Menin may also exert its functions via either its central pocket or other parts of its surface. Moreover, menin not only regulates multiple signaling pathways, but itself is also regulated by multiple proteins, signaling pathways and numerous

types of posttranslational modifications. It is noteworthy that these various mechanisms could be highly tissue-specific, or cell type or context-dependent, and more genetic and biochemical work remains to expand these observations. It is noteworthy that certain important findings were only observed in a limited number of studies or conditions; caution need to be exercised in generalizing such functions of menin and further detailed studies are expected to resolve these issues. Nevertheless, this progress has provided novel insights into how menin controls gene transcription and interplays with various signaling pathways. With the accumulation of this novel knowledge regarding the molecular mechanisms underlying the function of menin, many exciting questions (Box 1) can now be raised and addressed to improve the therapy of MEN1 disease and other related diseases such as leukemia. In particular, how does menin choose its partners in different contexts? For example, in MLL1 fusion protein (MFP)-induced leukemia, the interaction between menin and MLL1/MFP dimers is particularly important, as a menin/MLL1/MFP are required to maintain high level expression of HOX genes, which are crucial for MFP-induced leukemia. On the other hand, menin interaction with MLL1 may be important for upregulation of CDKI, p18 and p27 in endocrine cells, and menin interaction with JunD may be important to inhibit endocrine cells, but not necessary for MFP-induced leukemia. As such, further studies are necessary to explore these potential mechanisms.

Acknowledgments

We thank the close collaboration on studying the structural and functional relationship with Dr. Ming Lei's group, our colleagues for critically reading the manuscript, Ms. Erin Quinn for editing the manuscript. We also thank Dr. Chang-Xian Zhang for valuable discussion and inputs. This work was supported in part by grants from the NIH (R01-DK085121) and Caring for Carcinoid Foundation-AACR Grant Care for Carcinoid Foundation (11-60-33), and a TRP grant from Leukemia and Lymphoma Society. We apologize for being unable to cite all the relevant literatures due to limit of the space.

References

1. Chandrasekharappa SC, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. *Science*. 1997; 276:404–407. [PubMed: 9103196]
2. Lemmens I, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. *Hum Mol Genet*. 1997; 6:1177–1183. [PubMed: 9215690]
3. Agarwal SK, et al. Menin molecular interactions: insights into normal functions and tumorigenesis. *Horm Metab Res*. 2005; 37:369–374. [PubMed: 16001329]
4. Boikos SA, Stratakis CA. Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. *Hum Mol Genet*. 2007; 16(Spec No 1):R80–87. [PubMed: 17613552]
5. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. *Hum Mutat*. 2008; 29:22–32. [PubMed: 17879353]
6. Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. *Eur J Endocrinol*. 2005; 153:477–487. [PubMed: 16189167]
7. Thakker RV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). *J Clin Endocrinol Metab*. 2012; 97:2990–3011. [PubMed: 22723327]
8. Agarwal SK, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. *Hum Mol Genet*. 1997; 6:1169–1175. [PubMed: 9215689]
9. Carling T, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. *J Clin Endocrinol Metab*. 1998; 83:2960–2963. [PubMed: 9709976]
10. Jiao Y, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science*. 2011; 331:1199–1203. [PubMed: 21252315]

11. Bertolino P, et al. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. *Mol Endocrinol*. 2003; 17:1880–1892. [PubMed: 12819299]
12. Crabtree JS, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. *Proc Natl Acad Sci U S A*. 2001; 98:1118–1123. [PubMed: 11158604]
13. Harding B, et al. Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticotesteronaemia. *Endocr Relat Cancer*. 2009; 16:1313–1327. [PubMed: 19620250]
14. Guru SC, et al. Characterization of a MEN1 ortholog from *Drosophila melanogaster*. *Gene*. 2001; 263:31–38. [PubMed: 11223240]
15. Guru SC, et al. Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene. *Mamm Genome*. 1999; 10:592–596. [PubMed: 10341092]
16. Stewart C, et al. Characterization of the mouse Men1 gene and its expression during development. *Oncogene*. 1998; 17:2485–2493. [PubMed: 9824159]
17. Chen YX, et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. *Proc Natl Acad Sci U S A*. 2006; 103:1018–1023. [PubMed: 16415155]
18. Yokoyama A, et al. The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis. *Cell*. 2005; 123:207–218. [PubMed: 16239140]
19. Wu Y, et al. Interplay between menin and K-Ras in regulating lung adenocarcinoma. *J Biol Chem*. 2012; 287:40003–40011. [PubMed: 23027861]
20. Gao SB, et al. Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. *Oncogene*. 2009; 28:4095–4104. [PubMed: 19749796]
21. Seigne C, et al. Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice. *BMC Cancer*. 2010; 10:395. [PubMed: 20663219]
22. Seigne C, et al. High incidence of mammary intraepithelial neoplasia development in Men1-disrupted murine mammary glands. *J Pathol*. 229:546–558. [PubMed: 23180448]
23. Karnik SK, et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. *Science*. 2007; 318:806–809. [PubMed: 17975067]
24. Yang Y, et al. Reversal of preexisting hyperglycemia in diabetic mice by acute deletion of the Men1 gene. *Proc Natl Acad Sci U S A*. 2010; 107:20358–20363. [PubMed: 21059956]
25. Yang Y, et al. Deletion of the Men1 gene prevents streptozotocin-induced hyperglycemia in mice. *Exp Diabetes Res*. 2010; 2010:876701. [PubMed: 21318185]
26. Aziz A, et al. Menin expression modulates mesenchymal cell commitment to the myogenic and osteogenic lineages. *Dev Biol*. 2009; 332:116–130. [PubMed: 19464283]
27. Hendy GN, et al. Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. *Horm Metab Res*. 2005; 37:375–379. [PubMed: 16001330]
28. Inoue Y, et al. Menin interacts with beta-catenin in osteoblast differentiation. *Horm Metab Res*. 2011; 43:183–187. [PubMed: 21264795]
29. Kaji H. Menin and bone metabolism. *J Bone Miner Metab*. 2012; 30:381–387. [PubMed: 22543820]
30. Naito J, et al. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. *J Biol Chem*. 2005; 280:4785–4791. [PubMed: 15563473]
31. Sowa H, et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. *J Biol Chem*. 2004; 279:40267–40275. [PubMed: 15150273]
32. Cheng P, et al. Menin prevents liver steatosis through co-activation of peroxisome proliferator-activated receptor alpha. *FEBS Lett*. 2011; 585:3403–3408. [PubMed: 22001208]
33. Zindy PJ, et al. Upregulation of the tumor suppressor gene menin in hepatocellular carcinomas and its significance in fibrogenesis. *Hepatology*. 2006; 44:1296–1307. [PubMed: 17058241]
34. Canaff L, et al. Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA. *J Clin Endocrinol Metab*. 2012; 97:E282–291. [PubMed: 22090276]

35. Feng ZJ, et al. SUMO modification of menin. *Am J Cancer Res.* 2013; 3:96–106. [PubMed: 23359867]
36. MacConaill LE, et al. Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. *Mol Cancer Res.* 2006; 4:793–801. [PubMed: 17050672]
37. Yaguchi H, et al. Menin Missense Mutants Associated with Multiple Endocrine Neoplasia Type 1 Are Rapidly Degraded via the Ubiquitin-Proteasome Pathway. *Mol Cell Biol.* 2004; 24:6569–6580. [PubMed: 15254225]
38. Balogh K, et al. Menin and its interacting proteins: elucidation of menin function. *Trends Endocrinol Metab.* 2006; 17:357–364. [PubMed: 16997566]
39. Poisson A, et al. Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. *Cancer Letters.* 2003; 189:1–10. [PubMed: 12445671]
40. Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, Merchant JL, Hua X, Lei M. The same pocket in menin binds both MLL and JUND to produce opposite effects on transcription. *Nature.* 2012; 482:542–546. [PubMed: 22327296]
41. Murai MJ, et al. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. *J Biol Chem.* 2011; 286:31742–31748. [PubMed: 21757704]
42. Schnepp RW, et al. Mutation of tumor suppressor gene Men1 acutely enhances proliferation of pancreatic islet cells. *Cancer Res.* 2006; 66:5707–5715. [PubMed: 16740708]
43. Guru SC, et al. Menin, the product of the MEN1 gene, is a nuclear protein. *Proc Natl Acad Sci U S A.* 1998; 95:1630–1634. [PubMed: 9465067]
44. La P, et al. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. *Oncogene.* 2006; 25:3537–3546. [PubMed: 16449969]
45. Jin S, et al. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. *J Clin Invest.* 120:593–606. [PubMed: 20093773]
46. Lemmens IH, et al. Menin interacts directly with the homeobox-containing protein Pem. *Biochem Biophys Res Commun.* 2001; 286:426–431. [PubMed: 11500056]
47. Sowa H, et al. Menin is required for BMP-2- and TGF- β -regulated osteoblastic differentiation through interaction with Smads and Runx2. *J Biol Chem.* 2004
48. Hughes CM, et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. *Mol Cell.* 2004; 13:587–597. [PubMed: 14992727]
49. Yokoyama A, et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. *Mol Cell Biol.* 2004; 24:5639–5649. [PubMed: 15199122]
50. Agarwal SK, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. *Cell.* 1999; 96:143–152. [PubMed: 9989505]
51. Heppner C, et al. The tumor suppressor protein menin interacts with NF- κ B proteins and inhibits NF- κ B-mediated transactivation. *Oncogene.* 2001; 20:4917–4925. [PubMed: 11526476]
52. Shi K, et al. The embryonic transcription factor Hlxb9 is a menin interacting partner that controls pancreatic beta-cell proliferation and the expression of insulin regulators. *Endocr Relat Cancer.* 2013; 20:111–122. [PubMed: 23419452]
53. Gang D, et al. The tumor suppressor protein menin inhibits NF- κ B-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma. *Mol Biol Rep.* 2012
54. Gurung B, et al. Menin Epigenetically Represses Hedgehog signaling in MEN1 Tumor Syndrome. *Cancer Research.* 2013 In Press.
55. Kim H, et al. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. *Cancer Res.* 2003; 63:6135–6139. [PubMed: 14559791]
56. Kaji H, et al. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. *Proc Natl Acad Sci U S A.* 2001; 98:3837–3842. [PubMed: 11274402]
57. Bertolino P, et al. Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. *Cancer Res.* 2003; 63:4836–4841. [PubMed: 12941803]

58. Cao Y, et al. Nuclear-cytoplasmic shuttling of menin regulates nuclear translocation of {beta}-catenin. *Mol Cell Biol.* 2009; 29:5477–5487. [PubMed: 19651895]
59. Chen G, et al. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. *Mol Cancer Res.* 2008; 6:1894–1907. [PubMed: 19074834]
60. Veschi S, et al. Alterations of MEN1 and E-cadherin/beta-catenin complex in sporadic pulmonary carcinoids. *Int J Oncol.* 2012
61. Dreijerink KM, et al. Menin links estrogen receptor activation to histone H3K4 trimethylation. *Cancer Res.* 2006; 66:4929–4935. [PubMed: 16651450]
62. Dreijerink KM, et al. The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. *Mol Cell Biol.* 2009; 29:5060–5069. [PubMed: 19596783]
63. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. *Cancer Cell.* 2008; 14:36–46. [PubMed: 18598942]
64. Scacheri PC, et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. *PLoS Genet.* 2006; 2:406–419.
65. Wang P, et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. *Mol Cell Biol.* 2009; 29:6074–6085. [PubMed: 19703992]
66. Karnik SK, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. *Proc Natl Acad Sci U S A.* 2005; 102:14659–14664. [PubMed: 16195383]
67. Milne TA, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. *Proc Natl Acad Sci U S A.* 2005; 102:749–754. [PubMed: 15640349]
68. Lin W, et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. *Proc Natl Acad Sci U S A.* 2011; 108:13379–13386. [PubMed: 21788502]
69. Thiel AT, et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. *Cancer Cell.* 17:148–159. [PubMed: 20159607]
70. Thiel AT, et al. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPalpha and differentiation in MLL-AF9 leukemia. *Haematologica.* 2013
71. Lin C, et al. AFF4, a Component of the ELL/P-TEFb Elongation Complex and a Shared Subunit of MLL Chimeras, Can Link Transcription Elongation to Leukemia. *Mol Cell.* 37:429–437. [PubMed: 20159561]
72. Okada Y, et al. hDOT1L links histone methylation to leukemogenesis. *Cell.* 2005; 121:167–178. [PubMed: 15851025]
73. Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. *Nat Chem Biol.* 8:277–284. [PubMed: 22286128]
74. Shi A, et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. *Blood.* 120:4461–4469. [PubMed: 22936661]
75. Zhou H, et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. *J Med Chem.* 56:1113–1123. [PubMed: 23244744]
76. Wu T, et al. Regulation of cyclin B2 expression and cell cycle G2/m transition by menin. *J Biol Chem.* 2010; 285:18291–18300. [PubMed: 20404349]
77. Hernandez JM, et al. Multiple facets of junD gene expression are atypical among AP-1 family members. *Oncogene.* 2008; 27:4757–4767. [PubMed: 18427548]
78. Agarwal SK, et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. *Proc Natl Acad Sci U S A.* 2003; 100:10770–10775. [PubMed: 12960363]
79. Martinelli DC, Fan CM. Gas1 extends the range of Hedgehog action by facilitating its signaling. *Genes Dev.* 2007; 21:1231–1243. [PubMed: 17504940]
80. Luzi E, et al. The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases. *Nucleic Acid Ther.* 2012; 22:103–108. [PubMed: 22409234]

81. Rulifson IC, et al. Wnt signaling regulates pancreatic beta cell proliferation. *Proc Natl Acad Sci U S A*. 2007; 104:6247–6252. [PubMed: 17404238]
82. Imachi H, et al. Menin, a product of the MEN1 gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. *Breast Cancer Res Treat*. 2010; 122:395–407. [PubMed: 19847644]
83. Kim YS, et al. Stable overexpression of MEN1 suppresses tumorigenicity of RAS. *Oncogene*. 1999; 18:5936–5942. [PubMed: 10557080]
84. Gallo A, et al. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. *Oncogene*. 2002; 21:6434–6445. [PubMed: 12226747]
85. Feng ZJ, et al. Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP beta/zeta signaling by menin. *Oncogene*. 2010; 29:5416–5426. [PubMed: 20639902]
86. Wang Y, et al. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. *Cancer Res*. 2011; 71:371–382. [PubMed: 21127195]
87. Wuescher L, et al. Insulin regulates menin expression, cytoplasmic localization, and interaction with FOXO1. *Am J Physiol Endocrinol Metab*. 2011; 301:E474–483. [PubMed: 21693693]
88. Hughes E, Huang C. Participation of Akt, menin, and p21 in pregnancy-induced beta-cell proliferation. *Endocrinology*. 2011; 152:847–855. [PubMed: 21239436]
89. Zhang H, et al. Menin expression is regulated by transforming growth factor beta signaling in leukemia cells. *Chin Med J (Engl)*. 2011; 124:1556–1562. [PubMed: 21740816]
90. Mensah-Osman E, et al. Somatostatin stimulates menin gene expression by inhibiting protein kinase A. *Am J Physiol Gastrointest Liver Physiol*. 2008; 295:G843–854. [PubMed: 18755809]
91. Zhang H, et al. Glucose-mediated repression of menin promotes pancreatic beta-cell proliferation. *Endocrinology*. 2012; 153:602–611. [PubMed: 22166975]
92. Luzi E, et al. The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the “Knudson's second hit”. *PLoS ONE*. 2012; 7:e39767. [PubMed: 22761894]
93. Francis J, et al. The menin tumor suppressor protein is phosphorylated in response to DNA damage. *PLoS One*. 2011; 6:e16119. [PubMed: 21264250]
94. Busygina V, et al. Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. *Hum Mol Genet*. 2004; 13:2399–2408. [PubMed: 15333582]
95. Suphapeetiporn K, et al. MEN1 tumor-suppressor protein localizes to telomeres during meiosis. *Genes, Chromosomes & Cancer*. 2002; 35:81–85. [PubMed: 12203793]

Box 1: Outstanding questions

- How does menin choose its partner among a diverse group of interacting proteins? Does menin choose certain partners in distinct types of cells or in distinct settings of biological conditions?
- How does menin functionally interact with its partners *in vivo* in model organisms such as mice?
- How is menin regulated and how do various posttranslational modifications impact its function?
- How does menin exert its crucial functions in various organ systems in development, homeostasis, and disease?
- Can *MEN1* mutation-induced dysregulation of tumorigenic pathways, such as the Hedgehog signaling pathway, be targeted to improve therapy of MEN1 syndrome?
- Can the structure of menin be used to develop better inhibitors to treat relevant diseases such as MLL-FP-induced leukemia, perhaps by blocking menin-MLL/MLL-FP interactions?

Highlights

1. Molecular and structural basis for menin-mediated activation of gene transcription
2. Multiple modes and molecular basis of menin-mediated suppression of gene transcription
3. Menin regulates multiple cell signaling pathways
4. Menin is regulated by multiple factors and signaling pathways

Figure 1. Menin-interacting proteins and structures of menin with selected interacting proteins (A) Four classes of menin interacting proteins based on their cellular functions in context of their interaction with menin: Transcription activators; transcription repressors; cell signaling proteins; and other proteins. Some menin interacting proteins can have dual roles as transcription factors and signaling molecules. (B) The surface representation of menin complexed with MLL1_{MBM} (menin binding motif of MLL1). (C) Overall ternary structure of menin complexed with MLL1_{MBM}-LBM (MLL1 menin binding motif- LEDGF binding motif) and LEDGF_{IBM}. (D) Crystal structure of menin in complex with JunD peptide. Menin interacts directly with JunD. Menin binding motif of JunD consists of residues 27–47. JunD_{MBM} is shown as purple stick model. (B–D) Reprinted by permission from [40].

Figure 2. Menin acts as a scaffold protein to tissue-specifically activate gene transcription

(A) In endocrine cells, menin recruits MLL1 to the promoters of cyclin dependent kinase (CDK) inhibitors p18 and p27. (B) In MLL-FP-induced leukemia cells c-Myb binds and recruits menin. Menin further recruits, via its central pocket, either wildtype MLL1 (green and violet) or MLL1-FPs, recruitment of MLL (wildtype containing MLL-N and MLL-C or MLL1-FP) can help recruit LEDGF and Dot1L. Menin can directly deposit H3K4me3, while Dot1L deposits H3K79 methylation, both leading to increased transcription of *Hox* genes, *Meis1*, and *Ezh2*, and blockade of myeloid differentiation. Depiction of c-Myb is not stoichiometric in this figure.

Figure 3. Menin represses gene expression via multiple mechanisms

(A) Menin interacts with JunD and recruits the Sin3A/histone deacetylase (HDAC) complex to reduce histone acetylation and suppress the expression of JunD targets such as Gastrin.

The endogenous targets of JunD in this setting are unclear. (B) Menin also blocks JNK mediated phosphorylation of JunD, leading to repression of JunD transcriptional targets such as Gastrin. (C) In lung cancer cells, menin recruits EZH2 to the promoter of PTN to increase H3K27 trimethylation, a repressive mark, to downregulate the transcription of PTN.

Whether menin directly interacts with EZH2 is yet to be determined (D) Menin can inhibit Hedgehog signaling by interacting with PRMT5 at the Gas1 promoter in pancreatic islets to increase PRMT5-mediated symmetric H4R3 dimethylation, which inhibits the expression of Gas1 and therefore Hedgehog signaling.

Figure 4. Menin regulates multiple signaling pathways

Menin interacts with SMAD3 or SMAD1/5 to enhance TGFβ or BMP signaling, respectively, in various types of cells. Menin also interacts with NFκB and recruits Sirt1 to deacetylate p65 to suppress NFκB-induced gene expression. β-catenin is located in cell membrane, in presence of Wnt signaling it is translocated to the nucleus. In insulinoma cells, menin interacts with β-catenin to upregulate gene transcription, whether they associate with each other at the promoter of Axin 2 is not known. In contrast in MEFs, menin promotes nuclear export of β-catenin to suppress its transcriptional activity. Menin also interacts with nuclear receptors such as ERα to promote expression their target genes. In the cytoplasm, inhibits receptor tyrosine kinase signaling through multiple mechanisms: inhibition of AKT, inhibition of SOS1-dependent activation of Ras, and suppression of ERK activation.